Improving BNT162b2 mRNA Vaccine Tolerability without Efficacy Loss by Pidotimod Supplementation.
作者信息
Ucciferri Claudio, Vecchiet Jacopo, Auricchio Antonio, Falasca Katia
机构信息
Clinic of Infectious Diseases - Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara- Italy.
Department of Medicine and Health Sciences, University of Molise - Campobasso - Italy.
出版信息
Mediterr J Hematol Infect Dis. 2022 Mar 1;14(1):e2022023. doi: 10.4084/MJHID.2022.023. eCollection 2022.
Abstract
摘要
相似文献
1
Improving BNT162b2 mRNA Vaccine Tolerability without Efficacy Loss by Pidotimod Supplementation.通过补充匹多莫德提高BNT162b2 mRNA疫苗耐受性且不损失效力
Mediterr J Hematol Infect Dis. 2022 Mar 1;14(1):e2022023. doi: 10.4084/MJHID.2022.023. eCollection 2022.
2
Pfizer/BioNtech BNT162b2: adverse events and insights from an Australian mass vaccination clinic for COVID-19.辉瑞/生物科技 BNT162b2：澳大利亚大规模 COVID-19 疫苗接种诊所的不良事件和见解。
Intern Med J. 2022 Jan;52(1):121-124. doi: 10.1111/imj.15623.
3
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
4
Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study.新型 2019 冠状病毒病（COVID-19）疫苗在癫痫患者（PwE）中的安全性和耐受性：一项横断面研究。
Seizure. 2021 Nov;92:2-9. doi: 10.1016/j.seizure.2021.08.001. Epub 2021 Aug 6.
5
Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.COVID-19 疫苗加强针接种后的安全性监测-美国，2021 年 9 月 22 日-2022 年 2 月 6 日。
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):249-254. doi: 10.15585/mmwr.mm7107e1.
6
Side Effects of COVID-19 Pfizer-BioNTech mRNA Vaccine in Children Aged 12-18 Years in Saudi Arabia.沙特阿拉伯12至18岁儿童接种辉瑞-BioNTech新冠mRNA疫苗的副作用
Vaccines (Basel). 2021 Nov 9;9(11):1297. doi: 10.3390/vaccines9111297.
7
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.辉瑞-BioNTech 新冠疫苗在青少年中的安全性、免疫原性和有效性。
N Engl J Med. 2021 Jul 15;385(3):239-250. doi: 10.1056/NEJMoa2107456. Epub 2021 May 27.
8
Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. Veterans Affairs healthcare system.Moderna与辉瑞-生物科技公司新冠疫苗效果比较：美国退伍军人事务医疗系统中的一项目标试验模拟研究
EClinicalMedicine. 2022 Mar 5;45:101326. doi: 10.1016/j.eclinm.2022.101326. eCollection 2022 Mar.
9
COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021.2021 年 11 月 3 日至 12 月 19 日，美国 5-11 岁儿童的 COVID-19 疫苗安全性。
MMWR Morb Mortal Wkly Rep. 2021 Dec 31;70(5152):1755-1760. doi: 10.15585/mmwr.mm705152a1.
10
Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.BNT162b2 和 mRNA-1273 两种 SARS-CoV-2 疫苗接种后的 IgG 抗体反应差异。
Microbiol Spectr. 2021 Dec 22;9(3):e0116221. doi: 10.1128/Spectrum.01162-21. Epub 2021 Nov 10.
引用本文的文献
1
Pidotimod in pediatrics: new evidence and future perspectives.匹多莫德在儿科领域：新证据与未来展望。
Multidiscip Respir Med. 2024 Dec 12;19(1):986. doi: 10.5826/mrm.2024.986.
2
Immunogenicity and Efficacy of Vaccination in People Living with Human Immunodeficiency Virus.人类免疫缺陷病毒感染者接种疫苗的免疫原性和疗效
Viruses. 2023 Aug 30;15(9):1844. doi: 10.3390/v15091844.
3
Efficacy and Safety of COVID-19 Vaccination in Older Adults: A Systematic Review and Meta-Analysis.老年人接种新冠疫苗的有效性和安全性：一项系统评价与荟萃分析
Vaccines (Basel). 2022 Dec 23;11(1):33. doi: 10.3390/vaccines11010033.
4
A retrospective evaluation of side-effects associated with the booster dose of Pfizer-BioNTech/BNT162b2 COVID-19 vaccine among females in Eastern Province, Saudi Arabia.沙特阿拉伯东部省女性中辉瑞-生物科技/BNT162b2 COVID-19 疫苗加强针相关副作用的回顾性评估。
Vaccine. 2022 Nov 22;40(49):7087-7096. doi: 10.1016/j.vaccine.2022.10.009. Epub 2022 Oct 17.
本文引用的文献
1
Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021.Comirnaty（BNT162b2，辉瑞/生物科技）疫苗在意大利威尼托特雷维索省预防医护人员感染 SARS-CoV-2 的效果，2020 年 12 月 27 日至 2021 年 3 月 24 日。
Euro Surveill. 2021 Apr;26(17). doi: 10.2807/1560-7917.ES.2021.26.17.2100420.
2
Global dynamics of SARS-CoV-2 clades and their relation to COVID-19 epidemiology.SARS-CoV-2 进化枝的全球动态及其与 COVID-19 流行病学的关系。
Sci Rep. 2021 Apr 19;11(1):8435. doi: 10.1038/s41598-021-87713-x.
3
Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials.瑞德西韦治疗 COVID-19 患者的临床疗效和安全性：一项随机对照试验的系统评价和网络荟萃分析。
J Antimicrob Chemother. 2021 Jul 15;76(8):1962-1968. doi: 10.1093/jac/dkab093.
4
A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel.在以色列一家大型三级中心住院的 COVID-19 患者中评估瑞德西韦对病毒载量影响的真实环境评估。
Clin Microbiol Infect. 2021 Jun;27(6):917.e1-917.e4. doi: 10.1016/j.cmi.2021.02.029. Epub 2021 Mar 9.
5
BNT162b2 mRNA COVID-19 Vaccine: First Approval.BNT162b2 mRNA COVID-19 疫苗：首次批准。
Drugs. 2021 Mar;81(4):495-501. doi: 10.1007/s40265-021-01480-7.
6
Efficacy of canakinumab in mild or severe COVID-19 pneumonia.卡那奴单抗治疗轻症或重症 COVID-19 肺炎的疗效。
Immun Inflamm Dis. 2021 Jun;9(2):399-405. doi: 10.1002/iid3.400. Epub 2021 Jan 19.
7
Pidotimod and Immunological Activation in Individuals Infected with HIV.匹多莫德与 HIV 感染者的免疫激活。
Curr HIV Res. 2021;19(3):260-268. doi: 10.2174/1570162X18666210111102046.
8
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
9
Role of monoclonal antibody drugs in the treatment of COVID-19.单克隆抗体药物在新冠病毒疾病治疗中的作用。
World J Clin Cases. 2020 Oct 6;8(19):4280-4285. doi: 10.12998/wjcc.v8.i19.4280.
10
COVID-19 and mRNA Vaccines-First Large Test for a New Approach.新冠疫情与信使核糖核酸疫苗——新方法的首次大规模试验
JAMA. 2020 Sep 22;324(12):1125-1127. doi: 10.1001/jama.2020.16866.
Zotero 插件